Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH
(dalteparin) compared to placebo, both commenced beyond the immediate postoperative period,
for the prevention of VTE.